JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kranke, P.
Right arrow Articles by Tramèr, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kranke, P.
Right arrow Articles by Tramèr, M. R.
Related Collections
Right arrow Postanesthetic Care Unit
Right arrow Complications
Right arrow Pharmacology

Anesth Analg 2004;99:718-727
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000130589.00098.CD

ANESTHETIC PHARMACOLOGY

James G. Bovill Section Editor

Single-Dose Parenteral Pharmacological Interventions for the Prevention of Postoperative Shivering: A Quantitative Systematic Review of Randomized Controlled Trials

Peter Kranke, MD*, Leopold H. Eberhart, MD{dagger}, Norbert Roewer, MD*, and Martin R. Tramèr, MD DPhil{ddagger}

*Department of Anesthesiology, University of WÜrzburg, WÜrzburg, Germany; {dagger}Department of Anesthesia and Intensive Care, Philipps University of Marburg, Marburg, Germany; and {ddagger}Division of Anesthesiology, Geneva University Hospitals, Geneva, Switzerland

Address correspondence and reprint requests to Peter Kranke, MD, Department of Anesthesiology, University of WÜrzburg, OberdÜrrbacherstr. 6, D-97080 WÜrzburg, Germany. Address e-mail to kranke_p{at}klinik.uni-wuerzburg.de


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
Shivering is a frequent complication in the postoperative period. The relative efficacy of pharmacological interventions to prevent this phenomenon is not well understood. We performed a systematic search for full reports of randomized comparisons of prophylactic, parenteral, single-dose antishivering interventions with inactive control (placebo or no treatment). Variable doses were converted to fixed doses. Dichotomous data on the absence of shivering were analyzed by using relative benefit (RB) and number needed to treat (NNT) with 95% confidence intervals (CI). Data from 27 trials (1348 adults received an antishivering intervention; 931 were controls) were analyzed. The average incidence of shivering in controls was extremely frequent (52%). Clonidine 65–300 µg (1078 patients), meperidine 12.5–35 mg (250 patients), tramadol 35–220 mg (250 patients), and nefopam 6.5–11 mg (204 patients) were tested in at least 3 trials each. All were more effective than control. For clonidine, meperidine, and nefopam, there was some weak evidence of dose responsiveness. For small-dose clonidine (65–110 µg), the RB compared with control was 1.32 (95% CI, 1.16–1.51); for medium-dose clonidine (140–150 µg), the RB was 1.83 (95% CI, 1.47–2.27); and for large-dose clonidine (220–300 µg), the RB was 1.52 (95% CI, 1.30–1.78). For all clonidine regimens combined, the RB was 1.58 (95% CI, 1.43–1.74), with an NNT of 3.7. For all meperidine regimens combined, the RB was 1.67 (95% CI, 1.37–2.03), with an NNT of 3. For all tramadol regimens combined, the RB was 1.93 (95% CI, 1.56–2.39), with an NNT of 2.2. For all nefopam regimens combined, the RB was 2.62 (95% CI, 2.02–3.40), with an NNT of 1.7. Methylphenidate, midazolam, dolasetron, ondansetron, physostigmine, urapidil, and flumazenil were tested in no more than 3 trials each, with a limited number of patients.

IMPLICATIONS: With prophylactic clonidine or meperidine, the incidence of postoperative shivering may be reduced by a factor of approximately 1.6. When the baseline risk is extremely high, one in three to four patients may profit. Other interventions—for instance, nefopam—may be even more effective but have been less well studied.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
Shivering may occur as an adverse effect of surgery and anesthesia. It may be associated with an increase in oxygen consumption (1), intraocular or intracranial pressure, and with wound pain (2). Thus, both the prevention of shivering and the treatment of established shivering should be regarded as clinically relevant medical interventions in the perioperative period.

Shivering may happen as a response to hypothermia. This is one reason why patients’ body temperature should be kept within a normal range during surgery. However, shivering may also occur in normothermic patients (3). Moreover, adequate body warming is not always possible. In selected surgical patients, anesthesiologists may therefore wish to prevent shivering by using pharmacological strategies. Indeed, numerous studies have tested the efficacy of a large variety of interventions that are thought to prevent shivering in normothermic or hypothermic surgical patients. The relative efficacy of these interventions, however, remains unclear. In a previous article (4), we described the efficacy and potential for harm of pharmacological interventions used to treat established shivering in surgical patients. In this systematic review, we report on the efficacy and harm of pharmacological interventions for the prevention of postoperative shivering.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
Relevant studies were full reports of randomized comparisons of prophylactic pharmacological, parenteral, single-dose antishivering interventions (experimental intervention) compared with placebo or no treatment (control intervention) in surgical, postoperatively nonventilated, not actively cooled adult patients. For inclusion, studies had to report dichotomous data on the presence or absence of shivering at any time after surgery. We did not consider interventions that were given via the intrathecal, epidural, or oral routes or nonpharmacological interventions. Studies in any language were considered. We did not include data from retrospective analyses or studies without randomization, from abstracts, from nonsurgical settings, or from experimental studies in volunteers. Studies with fewer than 10 patients per group were excluded. Because there is no "gold standard" antishivering intervention, we included only randomized controlled trials with a placebo (or no treatment) control group; active-controlled trials (drug-to-drug comparisons) without an inactive control group were excluded.

Two authors (PK and MRT) independently searched the MEDLINE (from 1966), EMBASE (from 1974), and CENTRAL (Cochrane) databases by using different search strategies. Free text words used were "postoperative OR postanesthetic OR postanaesthetic," "shivering OR shaking OR tremor," "randomised OR randomized," and combinations of these. The last electronic searches were on July 5, 2003. Reference lists of retrieved reports and of relevant review articles were scanned. We did not contact authors or manufacturers.

All retrieved reports were checked for inclusion by one author (PK). Those definitely not relevant were excluded at that stage. All potentially relevant reports were read by at least two authors independently to assess the adequacy of randomization and blinding and the description of withdrawals according to the validated three-item, five-point Oxford score (5). The maximum score of an included randomized controlled trial was 5, and the minimum was 1 (at least described as a randomized trial).

From relevant reports we obtained information on patients, operations, doses, routes and timing of the administration of the study drugs, and end-points. A large variety of different end-points was reported in these trials. Because of this inconsistency and to reduce the risk of interpretational bias, we extracted only dichotomous data on the complete absence of shivering. Data on adverse drug reactions were extracted when they were reported in dichotomous form. Data were extracted by one author (PK) and checked by two others (LHE and MRT). Variable doses (for instance, milligrams per kilogram of body weight) were converted to fixed doses by using the average body weights of the study populations as reported in the original trials. If these were not stated, we calculated fixed doses by assuming a body weight of 70 kg. Consensus on quality scores and extracted data was reached by discussion.

A large variety of experimental interventions were tested in these trials, and some regimens were tested in only one trial. Because no major additional information was to be expected from interventions that were tested in a limited number of patients and because undue weight would be given to those, an a priori decision was made to estimate antishivering efficacy for only those interventions that were tested in at least three trials.

As an estimate of the statistical significance of a difference between experimental interventions and control, we calculated relative benefits (RB) as relative risks with 95% confidence intervals (CI) (6). We used a fixed-effect model throughout because heterogeneity tests lack sensitivity and because we pooled data only when they were clinically homogeneous (7). A statistically significant difference between experimental and control interventions was assumed when the 95% CI of the RB excluded 1. As an estimate of the clinical relevance of a difference, we calculated the number needed to treat (NNT) (8).

We tested for dose responsiveness by using two conservative assumptions. If one dose of an experimental intervention was not significantly different from control (i.e., if the 95% CI around the RB included 1) and if larger doses were consistently more effective than control, then we regarded this as weak evidence of dose responsiveness. Second, if the 95% CI around the RB of a smaller dose did not overlap with the point estimate of the RB of a larger dose, we regarded this as strong evidence of dose responsiveness. The incidences of shivering with experimental and control interventions were graphically plotted to explore the variability of the event rates. Data on adverse drug reactions were analyzed as for efficacy data. Analyses were performed by using Excel (Microsoft, Redmond, WA) and RevMan 4.1 (Cochrane Library software; Update Software, Oxford, UK).


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
We screened 72 potentially relevant randomized controlled trials. Forty-five were subsequently excluded. Fourteen tested continuous, target-controlled, or repetitive drug administrations (9–22). Thirteen studied intrathecally or epidurally administered drugs (23–31), an oral premedication (32), or nonpharmacological interventions (33–35). Two studies included profoundly hypothermic patients or patients who were actively cooled (36,37); one of those (37) was published as a full report in a subsequent article (38). Two articles did not contain dichotomous data (39,40). Seven studies were not randomized, or the randomization process was unclear (41–47). Three trials lacked an inactive control group (48–50). One used an experimental design to estimate shivering thresholds (51). In one study, patients were intubated and ventilated after surgery (52). Finally, 1 trial had group sizes <10 patients (53).

We eventually analyzed data from 27 randomized controlled trials (54–80) that were published between 1980 and 2002 (Table 1 ). In those, 1348 adults received an experimental intervention, and 931 patients were controls. The median group size was 30 patients (range, 10–140). The median Oxford scale was 3 (range, 2–4); 10 reports scored 1, 10 scored 2, and 7 scored 4. All trials had a placebo or a no-treatment control group; 11 (54,60,63,64,66,68–72,74) studied more than 1 experimental intervention or investigated different doses of an experimental intervention. In one trial, the experimental intervention was given by the IM route (67). In all others, drugs were given IV. All drugs were given as single-dose regimens; they could be classified as opioids (meperidine), {alpha}2-antagonists (clonidine), other centrally-acting analgesics (tramadol and nefopam), serotonin antagonists (dolasetron and ondansetron), benzodiazepines (midazolam), benzodiazepine antagonists (flumazenil), {alpha}-blocking drugs (urapidil), central nervous system stimulants (methylphenidate), and cholinesterase inhibitors (physostigmine).


View this table:
[in this window]
[in a new window]
  		Table 1. Pharmacological Prophylaxis of Postoperative Shivering: Analyzed Randomized Controlled Trials
 

View this table:
[in this window]
[in a new window]
  		Table 1. Continued
 
Of the 931 control patients, 484 were reported to shiver in the postoperative period; thus, the average control event rate was 52%. There was a large variability in control event rates; in some trials, rates were less than 20% (59,79) and in others were more than 70% (75,78). Sixteen trials (54–58,61,63,67,71–73,75,77,78,80) (59% of all) reported a 50% or more incidence of shivering in the control group. Fifteen trials (54–58,62,63,65–67,69,71,74,75,77) reported on the average core temperature of the study population. Temperatures were measured in the bladder or tympanic membrane or were esophageal, rectal, or oropharyngeal or nasopharyngeal temperatures; they varied from 34.3°C (77) to 36.5°C (57). Graphically, there was no obvious relationship between the average core temperatures and the incidence of shivering in control patients (Fig. 1). Therefore, and because we had excluded trials in which patients were profoundly hypothermic or actively cooled (36,37), we combined antishivering data across studies, independently of the average core temperatures.



View larger version (34K):
[in this window]
[in a new window]
  		Figure 1. Relationship between average core temperatures in control patients as reported in 15 trials that reported on core temperature and the incidence of shivering in control patients (i.e., the control event rate). Temperature recording was in the bladder or the tympanic membrane or was nasopharyngeal, esophageal, or oropharyngeal. The size of the bubbles represents the number of patients in the control groups.

 
Clonidine was the most frequently documented drug; it was tested in 14 trials with 978 patients (56,57,60,61,63,65,66,69–72,76,78,80). The quality and quantity of the available efficacy data allowed for three sensitivity analyses.

First, we tested the effect of the time point of clonidine administration on antishivering efficacy. In two trials, clonidine was given before induction (60,80); the combined RB compared with control was 1.29 (95% CI, 1.08–1.53). In 4 trials, clonidine was given at induction (56,61,76,78); the combined RB was 1.67 (95% CI, 1.38–2.03). In 8 trials, clonidine was given during surgery or at the end of anesthesia (57,63,65,66,69–72); the combined RB was 1.64 (95% CI, 1.40–1.68).

Second, we tested the effect of trial size on the efficacy of clonidine (Fig. 2). We arbitrarily grouped trials into 3 ranges by taking the number of patients in the control groups as a measure of size. In the 6 small trials (group size, 10–20 patients), the RB was 2.00 (95% CI, 1.60–2.50) (57,61,63,66,72,80). In the 5 medium trials (30 patients), the RB was 1.62 (95% CI, 1.38–1.89) (56,65,69–71). In the 3 largest trials (50–140 patients), the RB was 1.46 (95% CI, 1.27–1.68) (60,76,78).



View larger version (13K):
[in this window]
[in a new window]
  		Figure 2. Prevention of shivering with IV clonidine. The relationship is shown between trial size (as represented by the number of patients in the control group) and the efficacy of clonidine in preventing shivering compared with control (placebo). Subgroup analyses are shown for three arbitrarily chosen ranges of group sizes. A relative benefit >1 suggests superiority with clonidine. CI = confidence interval.

 
Third, we tested the effect of the clonidine dose on efficacy (Fig. 3). Because a large number of different doses were tested, we arbitrarily grouped regimens into 3 ranges of fixed doses: 65–110 µg, 140–150 µg, and 220–300 µg. With the smallest-dose range, RB compared with control was 1.32 (95% CI, 1.16–1.51); with the medium-dose range, the RB was 1.83 (95% CI, 1.47–2.27); and with the large-dose range, the RB was 1.61 (95% CI, 1.38–1.87).



View larger version (39K):
[in this window]
[in a new window]
  		Figure 3. Prevention of shivering with small-, medium-, and large-close clonidine. Dose ranges were chosen post hoc. Forest plots show a relative benefit with 95% confidence interval (CI) for absence of shivering with clonidine compared with control (placebo). Event rate scatters show incidences of shivering with clonidine and with control (placebo); each symbol represents one trial, and the area of the symbol is proportional to the trial size.

 
When data from all clonidine trials were combined, the average control event rate was 52%. The RB to prevent shivering compared with control was 1.58 (95% CI, 1.43–1.74), and the NNT was 3.7 (95% CI, 3.0–4.6).

Three further drugs—meperidine, nefopam, and tramadol—were tested in at least three trials. Five trials with 250 patients tested IV meperidine (63,64,66,67,71). Shivering was reported in 40% to 57% of controls (average, 50%). The size of control groups was between 15 patients (66) and 30 patients (67,71). Tested regimens were 0.3, 0.4, and 0.5 mg/kg; 12.5 mg; and 25 mg (Table 1). When variable doses were converted to fixed doses, the tested dose range was 12.5–35 mg. There was some evidence of dose responsiveness, because doses larger than 25 mg only were consistently more effective than control (Fig. 4A). When data from all meperidine regimens were combined, the RB was 1.67 (95% CI, 1.37–2.03), and the NNT was 3.0 (95% CI, 2.3–4.5).



View larger version (38K):
[in this window]
[in a new window]
  		Figure 4. Prevention of shivering with meperidine (A), nefopam (B), and tramadol (C). Regimens are fixed doses and variable doses (as used in the included trials) in parentheses. Forest plots show relative benefit with 95% confidence interval (CI) for the absence of shivering with experimental interventions compared with control (placebo). Event rate scatters show the incidence of shivering with active treatment (experimental interventions) and with control (placebo); each symbol represents one trial, and the area of the symbol is proportional to trial size. *Trials with two active arms; placebo patients were counted only once.

 
Five trials with 204 patients tested IV nefopam (54,72,73,75,77). Shivering was reported in 57% to 90% of controls (average, 64%). The size of the control groups was between 15 patients (73) and 30 patients (54). Tested regimens were 0.1 and 0.15 mg/kg and 10 mg (Table 1). When variable doses were converted to fixed doses, the tested dose range was 7–11 mg. All doses were more effective than control; however, there was no evidence of dose responsiveness (Fig. 4B). When data from all nefopam regimens were combined, the RB was 2.62 (95% CI, 2.02–3.40), and the NNT was 1.7 (95% CI, 1.4–2.0).

Three trials with 250 patients tested IV tramadol (54,58,68). Shivering was reported in 48% to 60% of controls (average, 53%). The size of the control groups was between 20 patients (58) and 50 patients (68). Tested regimens were 0.5, 1, 2, and 3 mg/kg (Table 1). When variable doses were converted to fixed doses, the tested dose range was 35–220 mg. There was increasing efficacy with increasing doses (Fig. 4C); the RB increased consistently from 1.77 with 35 mg (0.5 mg/kg) to 2.50 with 220 mg (3 mg/kg). Corresponding NNTs decreased from 3 to 1.7. When data from all tramadol regimens were combined, the RB was 1.93 (95% CI, 1.56–2.39), and the NNT was 2.2 (95% CI, 1.8–2.8).

Three trials with more than 2 arms compared clonidine 1.5, 2, or 3 µg/kg with meperidine 0.3, 0.4, or 0.5 mg/kg (63,66,71). With all 3 clonidine regimens combined, 58 (89%) of 65 patients did not shiver; with meperidine, 55 (85%) of 65 patients did not shiver (RB, 1.06; 95% CI, 0.91–1.22). No other drug-to-drug comparisons were tested in more than two trials.

All other interventions were tested in no more than two trials and with a limited number of patients. These were midazolam (60,62), dolasetron (55,69), urapidil (70,71), methylphenidate (59), physostigmine (66), ondansetron (74), and flumazenil (79).

Reporting of adverse effects was sparse. With clonidine, hypotension and bradycardia were reported (76,78,80). With meperidine (66) and tramadol (58,68), nausea and vomiting were reported. One trial that tested nefopam reported on drowsiness (77). None of the adverse effects was significantly associated with any of the experimental interventions.


   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
These trials suggest that fewer than four patients have to receive prophylactic clonidine for one not to shiver after surgery. For meperidine, nefopam, and tramadol, efficacy data seemed even more convincing. The nefopam trials, for instance, suggested that fewer than two patients have to receive that drug prophylactically for one to stay free of symptoms. However, we have to assume that this extraordinary degree of efficacy is flawed. The frequent incidence of shivering in the untreated control groups suggested that these trial populations had a very high baseline risk. Two problems emerge from this. First, these study populations do not necessarily represent those whom anesthesiologists see in daily clinical practice; this challenges the external validity of the trials. Second, although the NNT represents a valuable tool to quantify the effort that is needed to achieve one successful outcome, it has to be kept in mind that absolute measurements of treatment efficacy tend to overestimate an intervention’s usefulness when control event rates are extremely frequent. To get an impression of an intervention’s performance independently of the baseline risk, it may be more sensible to express efficacy in relative terms. These prophylactic interventions, for instance, have the potential to decrease the risk of postoperative shivering by a factor of 1.5 to 2.5. Keeping this degree of relative efficacy in mind, the performance of clonidine, tramadol, nefopam, and meperidine can be extrapolated to populations with much less risk of postoperative shivering. Obviously, in populations with lower baseline risks, the absolute degree of efficacy of these drugs will be weaker, and, thus, the NNTs to prevent shivering compared with placebo will be larger.

Clonidine has been tested in more trials than any other drug; therefore, sensitivity analyses could be performed to study the effect of dose and timing of administration. For best efficacy, clonidine should be administered no earlier than at induction, and doses should be larger than 140 µg. Similar analyses could not be performed for the other drugs because of a lack of relevant data.

Our analysis has some limitations; most are related to the original trials. First, for none of the tested molecules is the biological basis for their antishivering effect fully understood. Some may alter the shivering threshold. This has been demonstrated for meperidine (81) and clonidine (82). Second, we were unable to identify predictive factors for postoperative shivering. We had to rely on the incidence of shivering in control patients who received a placebo or no treatment (i.e., the control event rate) as a surrogate of the true underlying risk. Third, as in previous similar analyses (4), we had to rely on indirect comparisons to estimate the relative efficacy of these antishivering interventions. This was necessary because there is no gold standard against which all other interventions could be tested. However, it has been shown that results from meta-analyses of indirect comparisons are similar to those that include direct drug-to-drug comparisons (83). Data from three placebo-controlled trials that directly compared clonidine with meperidine confirmed the results from the indirect comparisons (63,66,71). Fourth, most trials were of limited size; 5 trials only included 50 or more patients per group (60,68,76,78,79); 4 of those tested clonidine. With clonidine, there was strong evidence that trial size affected antishivering efficacy; small trials overestimated treatment effect compared with larger trials. None of the other drugs was tested in trials of comparable size. When all trials were considered independent of size, the relative benefit for antishivering efficacy with nefopam was 2.62 (NNT, 1.7), and with clonidine it was 1.58 (NNT, 3.7). This indirect comparison suggests that nefopam was more effective than clonidine. Nefopam trials, however, had on average much smaller group sizes. When data from a subgroup of small clonidine trials were combined in a sensitivity analysis, the relative risk point estimate improved to 2.0 (NNT, 2.2) and thus came close to the values for nefopam.

This example strongly suggests that trial size should not be ignored when efficacy is estimated on the basis of data from indirect (placebo-controlled) comparisons. Fifth, the methodological quality of most trials was unsatisfactory. Twenty reports had a quality score of 2 or less on the five-point Oxford scale. Low quality scores also have been associated with biased estimates of efficacy. We were unable to conduct the necessary sensitivity analyses to confirm this because there were not enough high-quality trials. Finally, reporting of harm was sparse. A single dose of meperidine 30 mg or of nefopam 10 mg is unlikely to induce clinically relevant adverse effects. However, with clonidine 150 µg, we would expect bradycardia or hypotension in most patients. Lack of reporting of adverse effects does not mean that none occurred.

In conclusion, prophylaxis of postoperative shivering with simple pharmacological interventions is possible and clinically effective if the risk of developing postoperative shivering is very high. This begs the question of whether shivering should be prevented or if shivering patients should be treated. Treatment of established shivering was also shown to be very effective (4); indeed, NNTs to stop further shivering with meperidine or clonidine in a shivering patient were even less than for prophylaxis. However, in the treatment trials, observation periods were very short, often <10 minutes (4); thus, we do not know how these drugs perform long-term as a therapy of established shivering. With prophylaxis, many patients will receive a drug without actually needing it. These patients are unnecessarily exposed to adverse drug reactions. The fact that intraoperative body warming and maintaining core temperature per se have a major effect on the incidence of postoperative shivering (84) further puts into question the usefulness of pharmacological shivering prophylaxis. There may be a special case for selected patients with compromised cardiac oxygen supply; in these patients, it may be worthwhile to give an antishivering drug prophylactically, and clonidine may be the most rational choice, because in addition to its antishivering effect, it has a favorable effect on cardiac outcome (85). Finally, more knowledge about predictive factors for postoperative shivering is likely to further ameliorate the clinical management of patients at risk and, it is hoped, improve outcomes.


   Acknowledgments
 
Supported by the Jubilee Foundation from the University of WÜrzburg (PK) and Prosper Grant 3233-051939.97 from the Swiss National Science Foundation (MRT).

We thank Daniel Haake from the medical libraries of the Centre Medical Universitaire, Geneva University, Geneva, for his help in searching electronic databases. We are grateful to Keinosuke Nara, MD, PhD, and Alexander Stetsenko, MD, who translated relevant articles.


   Footnotes
 
Presented in part at the annual meeting of the American Society of Anesthesiologists, New Orleans, LA, October 13–17, 2001.

An extended version of a review on this topic is registered in the Cochrane Library.


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. Macintyre PE, Pavlin EG, Dwersteg JF. Effect of meperidine on oxygen consumption, carbon dioxide production, and respiratory gas exchange in postanesthesia shivering. Anesth Analg 1987; 66: 751–5.[Abstract/Free Full Text]
  2. Sessler DI. Temperature monitoring. In: Miller RD, ed. Anesthesia. New York: Churchill Livingstone, 1994: 1363–82.
  3. De Witte J, Sessler DI. Perioperative shivering: physiology and pharmacology. Anesthesiology 2002; 96: 467–84.[ISI][Medline]
  4. Kranke P, Eberhart LH, Roewer N, Tramèr MR. Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials. Anesth Analg 2002; 94: 453–60.[Abstract/Free Full Text]
  5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.[ISI][Medline]
  6. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratio, and standardised ratios and rates. In: Altman DG, Gardner MJ, eds. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Books, 1995: 50–63.
  7. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 2000; 85: 415–24.[ISI][Medline]
  8. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4.[Free Full Text]
  9. Alfonsi P, Sessler DI, Du MB, et al. The effects of meperidine and sufentanil on the shivering threshold in postoperative patients. Anesthesiology 1998; 89: 43–8.[ISI][Medline]
  10. Apitzsch H, Olthoff D, Thieme V, et al. The effects of perioperative continuous administration of mivazerol on early postoperative hemodynamics and plasma catecholamines after major surgery. Anasthesiol Intensivmed Notfallmed Schmerzther 2000; 35: 515–22.[ISI][Medline]
  11. Flacke JW, Bloor BC, Flacke WE, et al. Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 1987; 67: 11–9.[ISI][Medline]
  12. Hommeril JL, Bernard JM, Passuti N, et al. Effects of intravenous clonidine on postoperative shivering. Ann Fr Anesth Reanim 1991; 10: 554–8.[ISI][Medline]
  13. Jalonen J, Hynynen M, Kuitunen A, et al. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology 1997; 86: 331–45.[ISI][Medline]
  14. Kabutan K, Iwatsuki K, Nishimura Y, et al. The effect of vasodilator on the occurrence of postoperative shivering and the fall of core temperature. Masui 1997; 46: 669–73.[Medline]
  15. Kawaguchi M, Inoue S, Sakamoto T, et al. The effects of prostaglandin E1 on intraoperative temperature changes and the incidence of postoperative shivering during deliberate mild hypothermia for neurosurgical procedures. Anesth Analg 1999; 88: 446–51.[Abstract/Free Full Text]
  16. Matsukawa T, Hanagata K, Kumazawa T, et al. The effect of prostaglandin E1 (PGE1) on body temperature and on postoperative shivering under high dose epidural fentanyl. Masui 1991; 40: 1495–502.[Medline]
  17. Paech MJ, Pavy TJ, Orlikowski CE, Evans SF. Patient-controlled epidural analgesia in labor: the addition of clonidine to bupivacaine-fentanyl. Reg Anesth Pain Med 2000; 25: 34–40.[ISI][Medline]
  18. Quintin L, Roudot F, Roux C, et al. Effect of clonidine on the circulation and vasoactive hormones after aortic surgery. Br J Anaesth 1991; 66: 108–15.[Abstract/Free Full Text]
  19. Quintin L, Viale JP, Annat G, et al. Oxygen uptake after major abdominal surgery: effect of clonidine. Anesthesiology 1991; 74: 236–41.[ISI][Medline]
  20. Sahin A, Aypar Ü. Effect of amino acid solutions on intraoperative hypothermia and postoperative shivering. Acta Anaesthesiol Scand 2002; 46: 64–7.[ISI][Medline]
  21. Selldén E, Branstrom R, Brundin T. Preoperative infusion of amino acids prevents postoperative hypothermia. Br J Anaesth 1996; 76: 227–34.[Abstract/Free Full Text]
  22. Selldén E, Lindahl SG. Amino acid-induced thermogenesis reduces hypothermia during anesthesia and shortens hospital stay. Anesth Analg 1999; 89: 1551–6.[Abstract/Free Full Text]
  23. Breen TW, Janzen JA. Epidural fentanyl and caesarean section: when should fentanyl be given? Can J Anaesth 1992; 39: 317–22.[Abstract/Free Full Text]
  24. Chen JC, Hsu SW, Hu LH, et al. Intrathecal meperidine attenuates shivering induced by spinal anesthesia. Ma Zui Xue Za Zhi 1993; 31: 19–24.[Medline]
  25. Chow TC, Cho PH. The influence of small dose intrathecal fentanyl on shivering during transurethral resection of prostate under spinal anesthesia. Acta Anaesthesiol Sin 1994; 32: 165–70.[Medline]
  26. Chu CC, Shu SS, Lin SM, et al. The effect of intrathecal bupivacaine with combined fentanyl in cesarean section. Acta Anaesthesiol Sin 1995; 33: 149–54.[Medline]
  27. Lin BC, Lin PC, Lai YY, et al. The maternal and fetal effects of the addition of sufentanil to 0.5% spinal bupivacaine for cesarean delivery. Acta Anaesthesiol Sin 1998; 36: 143–8.[Medline]
  28. Liu WH, Luxton MC. The effect of prophylactic fentanyl on shivering in elective caesarean section under epidural analgesia. Anaesthesia 1991; 46: 344–8.[ISI][Medline]
  29. Palmer CM, Voulgaropoulos D, Alves D. Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Reg Anesth 1995; 20: 389–94.[ISI][Medline]
  30. Sutherland J, Seaton H, Lowry C. The influence of epidural pethidine on shivering during lower segment caesarean section under epidural anaesthesia. Anaesth Intensive Care 1991; 19: 228–32.[ISI][Medline]
  31. Vettermann J, Thomas H, Lischke V, Asskali F. Repeated addition of fentanyl to bupivacaine peridural analgesia in labor: clinical action and fentanyl plasma level. Anaesthesist 1996; 45: 428–36.[ISI][Medline]
  32. Mao CC, Tsou MY, Chia YY, et al. Pre-anesthetic oral clonidine is effective to prevent post-spinal shivering. Acta Anaesthesiol Sin 1998; 36: 137–42.[Medline]
  33. Camus Y, Delva E, Cohen S, Lienhart A. The effects of warming intravenous fluids on intraoperative hypothermia and postoperative shivering during prolonged abdominal surgery. Acta Anaesthesiol Scand 1996; 40: 779–82.[ISI][Medline]
  34. McEvoy MT, Carey TJ. Shivering and rewarming after cardiac surgery: comparison of ventilator circuits with humidifier and heated wires to heat and moisture exchangers. Am J Crit Care 1995; 4: 293–9.
  35. Mort TC, Rintel TD, Altman F. The effects of forced-air warming on postbypass central and skin temperatures and shivering activity. J Clin Anesth 1996; 8: 361–70.[ISI][Medline]
  36. Bilotta F, Pietropaoli P, La Rossa I, et al. Effects of shivering prevention on haemodynamic and metabolic demands in hypothermic postoperative neurosurgical patients. Anaesthesia 2001; 56: 514–9.[ISI][Medline]
  37. Yared JP, Starr NJ, Hoffmann-Hogg L, et al. Dexamethasone decreases the incidence of shivering after cardiac surgery: a randomized, double-blind, placebo-controlled study. Anesth Analg 1998; 87: 795–9.[Abstract/Free Full Text]
  38. Yared JP, Starr NJ, Torres FK, et al. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 2000; 69: 1420–4.[Abstract/Free Full Text]
  39. Brownridge P, Plummer J, Mitchell J, Marshall P. An evaluation of epidural bupivacaine with and without meperidine in labor. Reg Anesth 1992; 17: 15–21.[ISI][Medline]
  40. Frank T, Wehner M, Heinke W, Schmadicke I. Clonidine vs. midazolam for premedication: comparison of the anxiolytic effect by using the STAI-test. Anasthesiol Intensivmed Notfallmed Schmerzther 2002; 37: 89–93.[ISI][Medline]
  41. Brichard G, Johnstone M. The effect of methylphenidate (Ritalin) on post-halothane muscular spasticity. Br J Anaesth 1970; 42: 718–22.[Abstract/Free Full Text]
  42. Crossley AWA. Six months of shivering in a district general hospital. Anaesthesia 1992; 47: 845–8.[ISI][Medline]
  43. Goold JE. Postoperative spasticity and shivering: a review with personal observations of 500 patients. Anaesthesia 1984; 39: 35–8.[ISI][Medline]
  44. Hausmann D, Nadstawek J, Krajewski W. O2 uptake in the recovery period: the effect of the anesthetic procedure and the postoperative administration of pethidine. Anaesthesist 1991; 40: 229–34.[ISI][Medline]
  45. Saltanov AI, Boshkoev ZB, Kadyrova EG. Analgesia and treatment of muscular shivering during the period of postanesthetic adaptation in oncologic patients. Anesteziol Reanimatol 1998; 5: 32–5.
  46. Shehabi Y, Gatt S, Buckman T, Isert P. Effect of adrenaline, fentanyl and warming of injectate on shivering following extradural analgesia in labour. Anaesth Intensive Care 1990; 18: 31–7.[ISI][Medline]
  47. Svetlov VA, Kozlov SP, Sarkisova NG, Vashchinskaia TV. Shivering and rigor during the awakening period. Anesteziol Reanimatol 1994; 6: 12–6.
  48. Baxendale BR, Mahajan RP, Crossley AW. Anticholinergic premedication influences the incidence of postoperative shivering. Br J Anaesth 1994; 72: 291–4.[Abstract/Free Full Text]
  49. Erkola O, Korttila K, Aho M, et al. Comparison of intramuscular dexmedetomidine and midazolam premedication for elective abdominal hysterectomy. Anesth Analg 1994; 79: 646–53.[Abstract/Free Full Text]
  50. Frank T, Thieme V, Radow L. Premedication in maxillofacial surgery under total intravenous anesthesia: effects of clonidine compared to midazolam on the perioperative course. Anasthesiol Intensivmed Notfallmed Schmerzther 2000; 35: 428–34.[ISI][Medline]
  51. Wheelahan JM, Leslie K, Silbert BS. Epidural fentanyl reduces the shivering threshold during epidural lidocaine anesthesia. Anesth Analg 1998; 87: 587–90.[Abstract/Free Full Text]
  52. Zwischenberger JB, Kirsh MM, Dechert RE, et al. Suppression of shivering decreases oxygen consumption and improves hemodynamic stability during postoperative rewarming. Ann Thorac Surg 1987; 43: 428–31.[Abstract]
  53. Sevarino FB, Johnson MD, Lema MJ, et al. The effect of epidural sufentanil on shivering and body temperature in the parturient. Anesth Analg 1989; 68: 530–3.[Free Full Text]
  54. Bilotta F, Pietropaoli P, Sanita R, et al. Nefopam and tramadol for the prevention of shivering during neuraxial anesthesia. Reg Anesth Pain Med 2002; 27: 380–4.[ISI][Medline]
  55. Bock M, Sinner B, Göttlicher M, et al. Involvement of serotonergic pathways in postanaesthetic cold defence: dolasetron prevents shivering. J Thermal Biol 2002; 27: 159–66.
  56. Buggy D, Higgins P, Moran C, et al. Clonidine at induction reduces shivering after general anaesthesia. Can J Anaesth 1997; 44: 263–7.[Abstract/Free Full Text]
  57. Delaunay L, Bonnet F, Duvaldestin P. Clonidine decreases postoperative oxygen consumption in patients recovering from general anaesthesia. Br J Anaesth 1991; 67: 397–401.[Abstract/Free Full Text]
  58. de Witte J, Rietman GW, Vandenbroucke G, Deloof T. Post-operative effects of tramadol administered at wound closure. Eur J Anaesthesiol 1998; 15: 190–5.[ISI][Medline]
  59. Dodson ME, Fryer JM. Postoperative effects of methylphenidate. Br J Anaesth 1980; 52: 1265–70.[Abstract/Free Full Text]
  60. Eberhart LH, Novatchkov N, Schricker T, et al. Clonidine compared to midazolam for intravenous premedication for ambulatory procedures: a controlled double blind study in ASA 1 patients. Anasthesiol Intensivmed Notfallmed Schmerzther 2000; 35: 388–93.[ISI][Medline]
  61. Frank T, Thieme V, Olthoff D. Preoperative clonidine comedication within the scope of balanced inhalation anesthesia with sevoflurane in oral surgery procedures. Anaesthesiol Reanim 1999; 24: 65–70.[Medline]
  62. Grover VK, Mahajan R, Yaddanapudi LN, et al. Efficacy of midazolam in preventing postoperative shivering. Int J Clin Pharmacol Ther 2002; 40: 534–6.[ISI][Medline]
  63. Grundmann U, Berg K, Stamminger U, et al. Comparative study of pethidine and clonidine for prevention of postoperative shivering: a prospective, randomized, placebo-controlled double-blind study. Anasthesiol Intensivmed Notfallmed Schmerzther 1997; 32: 36–42.[ISI][Medline]
  64. Harris MM, Lawson D, Cooper CM, Ellis J. Treatment of shivering after epidural lidocaine. Reg Anesth 1989; 14: 13–8.[ISI][Medline]
  65. Horn EP, Werner C, Sessler DI, et al. Late intraoperative clonidine administration prevents postanesthetic shivering after total intravenous or volatile anesthesia. Anesth Analg 1997; 84: 613–7.[Abstract]
  66. Horn EP, Standl T, Sessler DI, et al. Physostigmine prevents postanesthetic shivering as does meperidine or clonidine. Anesthesiology 1998; 88: 108–13.[ISI][Medline]
  67. Hu LH, Chen JC, Lee Y, et al. Intramuscular meperidine for the prevention of shivering on spinal anesthesia. Ma Zui Xue Za Zhi 1992; 30: 223–8.[Medline]
  68. Mathews S, Al Mulla A, Varghese PK, et al. Postanaesthetic shivering: a new look at tramadol. Anaesthesia 2002; 57: 394–8.[ISI][Medline]
  69. Piper SN, Röhm KD, Maleck WH, et al. Dolasetron for preventing postanesthetic shivering. Anesth Analg 2002; 94: 106–11.[Abstract/Free Full Text]
  70. Piper SN, Fent MT, Röhm KD, et al. Urapidil does not prevent postanesthetic shivering: a dose-ranging study. Can J Anaesth 2001; 48: 742–7.[Abstract/Free Full Text]
  71. Piper SN, Maleck WH, Boldt J, et al. A comparison of urapidil, clonidine, meperidine and placebo in preventing postanesthetic shivering. Anesth Analg 2000; 90: 954–7.[Abstract/Free Full Text]
  72. Piper SN, Suttner SW, Schmidt CC, et al. Nefopam and clonidine in the prevention of postanaesthetic shivering. Anaesthesia 1999; 54: 695–9.[ISI][Medline]
  73. Piper SN, Schmidt CC, Suttner SW, et al. Prophylactic nefopam administration for post-anesthetic shivering. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33: 786–9.[ISI][Medline]
  74. Powell RM, Buggy DJ. Ondansetron given before induction of anesthesia reduces shivering after general anesthesia. Anesth Analg 2000; 90: 1423–7.[Abstract/Free Full Text]
  75. Rosa G, Pinto G, Orsi P, et al. Control of post anaesthetic shivering with nefopam hydrochloride in mildly hypothermic patients after neurosurgery. Acta Anaesthesiol Scand 1995; 39: 90–5.[ISI][Medline]
  76. Sia S. I.v. clonidine prevents post-extradural shivering. Br J Anaesth 1998; 81: 145–6.[Abstract/Free Full Text]
  77. Tempia A, Livigni S, Castino PM, et al. The use of nefopam in the prophylaxis and treatment of postoperative shivering. Minerva Anestesiol 1992; 58: 547–51.[Medline]
  78. Vanderstappen I, Vandermeersch E, Vanacker B, et al. The effect of prophylactic clonidine on postoperative shivering. Anaesthesia 1996; 51: 351–5.[ISI][Medline]
  79. Weinbroum AA, Gellee E. Flumazenil improves cognitive and neuromotor emergence and attenuates shivering after halothane-, enflurane- and isoflurane-based anesthesia. Can J Anaesth 2001; 48: 963–72.[Abstract/Free Full Text]
  80. Yang CH, Yu CC, Seah YS, et al. Effect of intravenous clonidine on prevention of postepidural shivering. Ma Zui Xue Za Zhi 1993; 31: 121–6.[Medline]
  81. Kurz A, Ikeda T, Sessler DI, et al. Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold. Anesthesiology 1997; 86: 1046–54.[ISI][Medline]
  82. Nicolaou G, Chen AA, Johnston CE, et al. Clonidine decreases vasoconstriction and shivering thresholds, without affecting the sweating threshold. Can J Anaesth 1997; 44: 636–42.[Abstract/Free Full Text]
  83. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472.[Abstract/Free Full Text]
  84. Buggy DJ, Crossley AW. Thermoregulation, mild perioperative hypothermia and postanaesthetic shivering. Br J Anaesth 2000; 84: 615–28.[Free Full Text]
  85. Stevens RD, Burri H, Tramèr MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesth Analg 2003; 97: 623–33.[Abstract/Free Full Text]
Accepted for publication April 5, 2004.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
C. Lysakowski, L. Dumont, C. Czarnetzki, and M. R. Tramer
Magnesium as an Adjuvant to Postoperative Analgesia: A Systematic Review of Randomized Trials
Anesth. Analg., June 1, 2007; 104(6): 1532 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
L. H. J. Eberhart, F. Doderlein, G. Eisenhardt, P. Kranke, D. I. Sessler, A. Torossian, H. Wulf, and A. M. Morin
Independent Risk Factors for Postoperative Shivering
Anesth. Analg., December 1, 2005; 101(6): 1849 - 1857.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kranke, P.
Right arrow Articles by Tramèr, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kranke, P.
Right arrow Articles by Tramèr, M. R.
Related Collections
Right arrow Postanesthetic Care Unit
Right arrow Complications
Right arrow Pharmacology

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999